David J. Arthur - 13 Feb 2023 Form 4 Insider Report for Salarius Pharmaceuticals, Inc. (SLRX)

Role
Chief Executive Officer, Director
Signature
/s/Mark Rosenblum, as Attorney-in-Fact
Issuer symbol
SLRX
Transactions as of
13 Feb 2023
Net transactions value
$0
Form type
4
Filing time
15 Feb 2023, 15:04:16 UTC
Previous filing
05 Jan 2023
Next filing
12 Apr 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SLRX Common Stock Award $0 +14,300 +42% $0.000000 48,019 13 Feb 2023 Direct F1
holding SLRX Common Stock 564 13 Feb 2023 By son
holding SLRX Common Stock 552 13 Feb 2023 By daughter
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Restricted stock granted under the Salarius Pharmaceuticals, Inc. 2015 Equity Incentive Plan in lieu of cash for performance bonus. The shares of common stock are subject to a six-month holding period pursuant to the terms of the restricted stock agreement.